Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10587 in MTAP-Deleted Advanced Solid Tumors
NCT07567859Phase 1Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of HS-10587 in solid tumor, sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Incidence of Dose-Limiting Toxicity at 21 days and Maximum Tolerated Dose or Maximum Administered Dose at 21 days. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
HS-10587
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07567859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07567859.